<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39373132</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2691-1299</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Current protocols</Title><ISOAbbreviation>Curr Protoc</ISOAbbreviation></Journal><ArticleTitle>Detection of Neutralizing Antibodies in Serum Samples Using a SARS-CoV-2 Pseudotyped Virus Assay.</ArticleTitle><Pagination><StartPage>e70025</StartPage><MedlinePgn>e70025</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpz1.70025</ELocationID><Abstract><AbstractText>Conventional live virus research on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease-19 (COVID-19), requires Biosafety Level 3 (BSL-3) facilities. SARS-CoV-2 pseudotyped viruses have emerged as valuable tools in virology, mimicking the entry process of the SARS-CoV-2 virus into human cells by expressing its spike glycoprotein in a surrogate system using recombinant plasmids. One significant application of this tool is in functional assays for the evaluation of neutralizing antibodies. Pseudotyped viruses have the advantage of being competent for only a single cycle of infection, providing better safety and versatility and allowing them to be studied in BSL-2 laboratories. Here, we describe three protocols for the detection of SARS-CoV-2 neutralizing antibodies through a pseudotyped virus assay. First, SARS-CoV-2 S pseudotyped viruses (PV SARS-CoV-2 S) are produced using a Moloney murine leukemia virus (MuLV) three-plasmid system. The plasmids are designed to express the GagPol packing proteins, enhanced green fluorescent protein (eGFP) as a readout system, and the SARS-CoV-2 S protein modified to remove the endoplasmic reticulum retention domain and to improve infection. Next, the internalization of PV SARS-CoV-2 S protein in human embryonic kidney 293T (HEK-293T) cells overexpressing angiotensin-converting enzyme 2 (HEK-293T-ACE2) is confirmed by fluorescence microscopy and quantified using flow cytometry. Finally, PV SARS-CoV-2 S is used to screen neutralizing antibodies in serum samples from convalescent COVID-19 patients; it can also be used for studying the cell entry mechanisms of different SARS-CoV-2 variants, evaluating antiviral agents, and designing vaccines. © 2024 Wiley Periodicals LLC. Basic Protocol 1: Generation of PV SARS-CoV-2 S pseudotyped virus Basic Protocol 2: Assay of PV SARS-CoV-2 S internalization in target cells. Basic Protocol 3: Detection of neutralizing antibodies in serum samples.</AbstractText><CopyrightInformation>© 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferrero</LastName><ForeName>Sol</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmaceutical Biotechnology, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batto</LastName><ForeName>María Victoria</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmaceutical Biotechnology, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gatto</LastName><ForeName>Matías Iván</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmaceutical Biotechnology, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimase</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hemotherapy Division, Hospital Militar Central 601 Cirujano Mayor Dr. Cosme Argerich, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helguera</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-1509-3564</Identifier><AffiliationInfo><Affiliation>Laboratory of Pharmaceutical Biotechnology, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Protoc</MedlineTA><NlmUniqueID>101773894</NlmUniqueID><ISSNLinking>2691-1299</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089942" MajorTopicYN="N">Viral Pseudotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">internalization assay</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">pseudotyped virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39373132</ArticleId><ArticleId IdType="doi">10.1002/cpz1.70025</ArticleId></ArticleIdList><ReferenceList><Title>Literature Cited</Title><Reference><Citation>Abraham, J., Corbett, K. D., Farzan, M., Choe, H., &amp; Harrison, S. C. (2010). Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses. Nature Structural &amp; Molecular Biology, 17(4), 438–444. https://doi.org/10.1038/nsmb.1772</Citation></Reference><Reference><Citation>Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Asthagiri Arunkumar, G., Jurczyszak, D., Polanco, J., Bermudez‐Gonzalez, M., Kleiner, G., Aydillo, T., Miorin, L., Fierer, D., Amarilis Lugo, L., Milunka Kojic, E., Stoever, J., Liu, S. T. H., … Krammer, F. (2020). A serological assay to detect SARS‐CoV‐2 seroconversion in humans. Nature Medicine, 26(7), 1033–1036. https://doi.org/10.1038/s41591‐020‐0913‐5</Citation></Reference><Reference><Citation>Basu, A., Mills, D. M., &amp; Bowlin, T. L. (2010). High‐throughput screening of viral entry inhibitors using pseudotyped virus. Current Protocols in Pharmacology, 51(1). https://doi.org/10.1002/0471141755.ph13b03s51</Citation></Reference><Reference><Citation>Bewley, K. R., Coombes, N. S., Gagnon, L., McInroy, L., Baker, N., Shaik, I., St‐Jean, J. R., St‐Amant, N., Buttigieg, K. R., Humphries, H. E., Godwin, K. J., Brunt, E., Allen, L., Leung, S., Brown, P. J., Penn, E. J., Thomas, K., Kulnis, G., Hallis, B., … Charlton, S. (2021). Quantification of SARS‐CoV‐2 neutralizing antibody by wild‐type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nature Protocols, 16(6), 3114–3140. https://doi.org/10.1038/s41596‐021‐00536‐y</Citation></Reference><Reference><Citation>Cantoni, D., Wilkie, C., Bentley, E. M., Mayora‐Neto, M., Wright, E., Scott, S., Ray, S., Castillo‐Olivares, J., Heeney, J. L., Mattiuzzo, G., &amp; Temperton, N. J. (2023). Correlation between pseudotyped virus and authentic virus neutralization assays, a systematic review and meta‐analysis of the literature. Frontiers in Immunology, 14, 1184362. https://doi.org/10.3389/fimmu.2023.1184362</Citation></Reference><Reference><Citation>Clark, L. E., Mahmutovic, S., Raymond, D. D., Dilanyan, T., Koma, T., Manning, J. T., Shankar, S., Levis, S. C., Briggiler, A. M., Enria, D. A., Wucherpfennig, K. W., Paessler, S., &amp; Abraham, J. (2018). Vaccine‐elicited receptor‐binding site antibodies neutralize two New World hemorrhagic fever arenaviruses. Nature Communications, 9(1), 1884. https://doi.org/10.1038/s41467‐018‐04271‐z</Citation></Reference><Reference><Citation>Condor Capcha, J. M., Lambert, G., Dykxhoorn, D. M., Salerno, A. G., Hare, J. M., Whitt, M. A., Pahwa, S., Jayaweera, D. T., &amp; Shehadeh, L. A. (2021). Generation of SARS‐CoV‐2 spike pseudotyped virus for viral entry and neutralization assays: A 1‐week protocol. Frontiers in Cardiovascular Medicine, 7, 618651. https://doi.org/10.3389/fcvm.2020.618651</Citation></Reference><Reference><Citation>Crawford, K. H. D., Eguia, R., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., Pettie, D., King, N. P., Balazs, A. B., &amp; Bloom, J. D. (2020). Protocol and reagents for pseudotyping lentiviral particles with SARS‐CoV‐2 spike protein for neutralization assays. Viruses, 12(5), 513. https://doi.org/10.3390/v12050513</Citation></Reference><Reference><Citation>Ferrero, S., Flores, M. D., Short, C., Vazquez, C. A., Clark, L. E., Ziegenbein, J., Zink, S., Fuentes, D., Payes, C., Batto, M. V., Collazo, M., García, C. C., Abraham, J., Cordo, S. M., Rodriguez, J. A., &amp; Dutch, R. E. (2021). Antibody‐based inhibition of pathogenic New World hemorrhagic fever mammarenaviruses by steric occlusion of the human transferrin receptor 1 apical domain. Journal of Virology, 95(17), e0186820. https://doi.org/10.1128/jvi.01868‐20</Citation></Reference><Reference><Citation>Gillot, C., Favresse, J., David, C., Maloteau, V., Dogne, J.‐M., &amp; Douxfils, J. (2024). An evaluation of a SARS‐CoV‐2 pseudovirus neutralization test and a comparison to a SARS‐CoV‐2 surrogate virus neutralization test in a COVID‐19 long‐term follow‐up cohort. Microbiology Research, 15(1), 422–430. https://doi.org/10.3390/microbiolres15010028</Citation></Reference><Reference><Citation>Gozalbo‐Rovira, R., Gimenez, E., Latorre, V., Francés‐Gómez, C., Albert, E., Buesa, J., Marina, A., Blasco, M. L., Signes‐Costa, J., Rodríguez‐Díaz, J., Geller, R., &amp; Navarro, D. (2020). SARS‐CoV‐2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID‐19 patients. Journal of Clinical Virology, 131, 104611. https://doi.org/10.1016/j.jcv.2020.104611</Citation></Reference><Reference><Citation>Helguera, G., Jemielity, S., Abraham, J., Cordo, S. M., Martinez, M. G., Rodriguez, J. A., Bregni, C., Wang, J. J., Farzan, M., Penichet, M. L., Candurra, N. A., &amp; Choe, H. (2012). An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic fever arenaviruses. Journal of Virology, 86(7), 4024–4028. https://doi.org/10.1128/JVI.06397‐11</Citation></Reference><Reference><Citation>Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., Hastie, K. M., Parker, M. D., Partridge, D. G., Evans, C. M., Freeman, T. M., de Silva, T. I., &amp; Wyles, M. D. (2020). Tracking changes in SARS‐CoV‐2 spike: Evidence that D614G increases infectivity of the COVID‐19 virus. Cell, 182(4), 812–827.e819. https://doi.org/10.1016/j.cell.2020.06.043</Citation></Reference><Reference><Citation>Mahmutovic, S., Clark, L., Levis, S. C., Briggiler, A. M., Enria, D. A., Harrison, S. C., &amp; Abraham, J. (2015). Molecular basis for antibody‐mediated neutralization of New World hemorrhagic fever mammarenaviruses. Cell Host &amp; Microbe, 18(6), 705–713. https://doi.org/10.1016/j.chom.2015.11.005</Citation></Reference><Reference><Citation>Manak, M., Gagnon, L., Phay‐Tran, S., Levesque‐Damphousse, P., Fabie, A., Daugan, M., Khan, S. T., Proud, P., Hussey, B., Knott, D., Charlton, S., Hallis, B., Medigeshi, G. R., Garg, N., Anantharaj, A., Raqib, R., Sarker, P., Alam, M. M., Rahman, M., … Carless, J. (2024). Standardised quantitative assays for anti‐SARS‐CoV‐2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: A qualification analysis. The Lancet Microbe, 5(3), e216–e225. https://doi.org/10.1016/s2666‐5247(23)00324‐5</Citation></Reference><Reference><Citation>Meng, E. C., Goddard, T. D., Pettersen, E. F., Couch, G. S., Pearson, Z. J., Morris, J. H., Ferrin, T. E. (2023). UCSF ChimeraX: Tools for structure building and analysis. Protein Science, 32, 4792. https://doi.org/10.1002/pro.4792</Citation></Reference><Reference><Citation>Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., Lu, Q., Li, X., Sun, Q., Liu, J., Fan, C., Huang, W., Xu, M., &amp; Wang, Y. (2020). Establishment and validation of a pseudovirus neutralization assay for SARS‐CoV‐2. Emerging Microbes Infection, 9(1), 680–686. https://doi.org/10.1080/22221751.2020.1743767</Citation></Reference><Reference><Citation>Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., Lu, Q., Li, X., Sun, Q., Liu, J., Fan, C., Huang, W., Xu, M., &amp; Wang, Y. (2020). Quantification of SARS‐CoV‐2 neutralizing antibody by a pseudotyped virus‐based assay. Nature Protocols, 15(11), 3699–3715. https://doi.org/10.1038/s41596‐020‐0394‐5</Citation></Reference><Reference><Citation>Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., Xiang, Z., Mu, Z., Chen, X., Chen, J., Hu, K., Jin, Q., Wang, J., &amp; Qian, Z. (2020). Characterization of spike glycoprotein of SARS‐CoV‐2 on virus entry and its immune cross‐reactivity with SARS‐CoV. Nature Communications, 11(1), 1620. https://doi.org/10.1038/s41467‐020‐15562‐9</Citation></Reference><Reference><Citation>Phelan, K., &amp; May, K. M. (2015). Basic techniques in mammalian cell tissue culture. Current Protocols in Pharmacology and Cell Biology, 66(1), A.3B.1–A.3B.22. https://doi.org/10.1002/0471143030.cb0101s66.</Citation></Reference><Reference><Citation>Radoshitzky, S. R., Abraham, J., Spiropoulou, C. F., Kuhn, J. H., Nguyen, D., Li, W., Nagel, J., Schmidt, P. J., Nunberg, J. H., Andrews, N. C., Farzan, M., &amp; Choe, H. (2007). Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature, 446(7131), 92–96. https://doi.org/10.1038/nature05539</Citation></Reference><Reference><Citation>Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.‐H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., Agudelo, M., Cho, A., Wang, Z., Gazumyan, A., Cipolla, M., Caskey, M., Robbiani, D. F., Nussenzweig, M. C., Rice, C. M., … Bieniasz, P. D. (2020). Measuring SARS‐CoV‐2 neutralizing antibody activity using pseudotyped and chimeric viruses. Journal of Experimental Medicine, 217(11), e20201181. https://doi.org/10.1084/jem.20201181</Citation></Reference><Reference><Citation>Seow, J., Khan, H., Rosa, A., Calvaresi, V., Graham, C., Pickering, S., Pye, V. E., Cronin, N. B., Huettner, I., Malim, M. H., Politis, A., Cherepanov, P., &amp; Doores, K. J. (2022). A neutralizing epitope on the SD1 domain of SARS‐CoV‐2 spike targeted following infection and vaccination. Cell Reports, 40(8), 111276. https://doi.org/10.1016/j.celrep.2022.111276</Citation></Reference><Reference><Citation>Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Kirkpatrick, E., Meade, P., Brito, R. N., Teo, C., McMahon, M., Simon, V., &amp; Krammer, F. (2020). SARS‐CoV‐2 seroconversion in humans: A detailed protocol for a serological assay, antigen production, and test setup. Current Protocols in Microbiology, 57(1), e100. https://doi.org/10.1002/cpmc.100</Citation></Reference><Reference><Citation>Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., Loschko, J., Maddur, M. S., Ota‐Setlik, A., Tompkins, K., Cole, J., Lui, B. G., Ziegenhals, T., Plaschke, A., Eisel, D., … Sahin, U. (2021). BNT162b vaccines protect rhesus macaques from SARS‐CoV‐2. Nature, 592(7853), 283–289. https://doi.org/10.1038/s41586‐021‐03275‐y</Citation></Reference><Reference><Citation>Walls, A. C., Park, Y.‐J., Tortorici, M. A., Wall, A., McGuire, A. T., &amp; Veesler, D. (2020). Structure, function, and antigenicity of the SARS‐CoV‐2 spike glycoprotein. Cell, 181(2), 281–292.e286. https://doi.org/10.1016/j.cell.2020.02.058</Citation></Reference><Reference><Citation>Wohlgemuth, N., Whitt, K., Cherry, S., Kirkpatrick Roubidoux, E., Lin, C.‐Y., Allison, K. J., Gowen, A., Freiden, P., Allen, E. K., St. Jude Investigative Team, Gaur, A. H., Estepp, J. H., Tang, L., Mori, T., Hijano, D. R., Hakim, H., McGargill, M. A., Krammer, F., Whitt, M. A., … Perez, D. R. (2021). An assessment of serological assays for SARS‐CoV‐2 as surrogates for authentic virus neutralization. Microbiology Spectrum, 9(2), e0105921. https://doi.org/10.1128/Spectrum.01059‐21</Citation></Reference><Reference><Citation>Yang, T. J., Yu, P. Y., Chang, Y. C., &amp; Hsu, S. T. D. (2021). D614G mutation in the SARS‐CoV‐2 spike protein enhances viral fitness by desensitizing it to temperature‐dependent denaturation. Journal of Biological Chemistry, 297(4), 101238. https://doi.org/10.1016/j.jbc.2021.101238</Citation></Reference><Reference><Citation>Zhang, L., Jackson, C. B., Mou, H., Ojha, A., Peng, H., Quinlan, B. D., Rangarajan, E. S., Pan, A., Vanderheiden, A., Suthar, M. S., Li, W., Izard, T., Rader, C., Farzan, M., &amp; Choe, H. (2020). SARS‐CoV‐2 spike‐protein D614G mutation increases virion spike density and infectivity. Nature Communications, 11(1), 6013. https://doi.org/10.1038/s41467‐020‐19808‐4</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>